Celularity (NASDAQ:CELU) versus HUTCHMED (NASDAQ:HCM) Financial Comparison

Celularity (NASDAQ:CELU) and HUTCHMED (NASDAQ:HCM) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, risk, valuation, earnings, institutional ownership, analyst recommendations and profitability.

Profitability

This table compares Celularity and HUTCHMED’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Celularity	-198.75%	N/A	-65.03%
HUTCHMED	N/A	N/A	N/A

Institutional & Insider Ownership

19.0% of Celularity shares are held by institutional investors. Comparatively, 8.8% of HUTCHMED shares are held by institutional investors. 17.3% of Celularity shares are held by company insiders. Comparatively, 3.6% of HUTCHMED shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Celularity and HUTCHMED, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celularity	1	0	1	0	2.00
HUTCHMED	1	3	1	1	2.33

Celularity currently has a consensus price target of $6.00, suggesting a potential upside of 370.59%. HUTCHMED has a consensus price target of $20.88, suggesting a potential upside of 35.20%. Given Celularity’s higher probable upside, equities analysts clearly believe Celularity is more favorable than HUTCHMED.

Valuation & Earnings

This table compares Celularity and HUTCHMED”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celularity	$54.22 million	0.68	-$57.89 million	($3.33)	-0.38
HUTCHMED	$630.20 million	4.27	$37.73 million	N/A	N/A

HUTCHMED has higher revenue and earnings than Celularity.

Risk & Volatility

Celularity has a beta of 0.8, indicating that its share price is 20% less volatile than the S&P 500. Comparatively, HUTCHMED has a beta of 0.42, indicating that its share price is 58% less volatile than the S&P 500.

Summary

HUTCHMED beats Celularity on 7 of the 11 factors compared between the two stocks.

About Celularity

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. It is also developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. It also produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. The company was founded in 1998 and is based in Florham Park, New Jersey.

About HUTCHMED

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.